Healthcare and Medical

home | healthcare and medical | company profile

£265.00
Report Delivery: Via Email
Alerts
Change Currency EuroUSDGBP

Lev Pharmaceuticals Inc - Premium Company Profile (Datamonitor)

  • Market: Healthcare and Medical
  • Published Date: 22/04/2008
  • Report Title: Lev Pharmaceuticals Inc - Premium Company Profile
  • Table of Contents: View Table of Contents
  • Report Type: Company Profile
  • Country: Global
  • Number of Pages: 34
Introduction

Lev Pharmaceuticals is a development stage biopharmaceutical company engaged in developing and commercializing therapeutics based on C1-esterase inhibitor (C1-INH) for the treatment of inflammatory diseases. Cinryze, the company’s lead drug candidate, is being developed for acute and prophylactic treatment of hereditary angioedema (HAE).

Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


  • Highlights

    Lev Pharmaceuticals in-licensed C1-INH from Sanquin in 2004. C1-INH is a human plasma protein that mediates inflammation and coagulation.

    Besides the current pipeline candidates, Lev Pharmaceuticals is also studying the use of C1-INH in the treatment of other inflammation-linked diseases such as gram-negative septicemia, inflammatory bowel disease, Alzheimer's disease and stroke.

    The company did not record revenues during the period 2002-2006 because the company currently does market any products, and has no other source of revenues. Lev Pharmaceuticals forecasts to derive 100% of its revenues from the sales of Cinryze. The total revenues will grow from $43 million in 2008 to $143 million in 2010.

    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company’s adjusted five year financial data along with key ratios and market capitalization
  • £265.00   Share Report
     
    Alerts  

    Purchase Information

    There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.

    Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.

    Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.

    Worldpay Logo
    Chancy Currency EUR USD GBP
    Customer Area
    English Italian Spanish French German Russian Chinese Arabic